Amgen Ending Heart-Failure Collaboration With Cytokinetics
November 23 2020 - 10:33AM
Dow Jones News
By Colin Kellaher
Amgen Inc. on Monday said it is ending its heart-failure
collaboration with Cytokinetics Inc. following disappointing study
results.
The Thousand Oaks, Calif., biotechnology company said it will
transition the development and commercialization rights for
omecamtiv mecarbil and AMG 594 to Cytokinetics, effective May 20,
2021.
Amgen and Cytokinetics last month said a pivotal Phase 3 study
of omecamtiv mecarbil in patients with heart failure met its
primary composite endpoint but missed its secondary endpoint. The
drug showed a statistically significant effect to reduce
cardiovascular death or heart failure events compared to placebo in
patients with heart failure with reduced ejection fraction, but no
reduction in the secondary endpoint of cardiovascular death was
observed.
Amgen, which in 2006 formed a collaboration with South San
Francisco, Calif., biopharmaceutical company Cytokinetics to
discover, develop and commercialize potential treatments for heart
failure, on Monday said it remains committed to its
cardiovascular-disease program, but that the study results "did not
meet the high bar we had set."
Cytokinetics said it is committed to advancing omecamtiv
mecarbil, citing the positive results in the primary endpoint. The
company said it has received positive feedback from key
heart-failure opinion leaders, with particular interest in the
potential role of the drug for patients who remain at risk for
hospitalization despite being treated with standard-of-care
regimens.
Cytokinetics said it expects to seek regulatory feedback
regarding a potential registration path for omecamtiv mecarbil,
subject to cooperation and transitions from Amgen.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 23, 2020 10:18 ET (15:18 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Sep 2023 to Sep 2024